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PIH44 WORK PRODUCTIVITY OF WOMEN EXPERIENCING DOMESTIC VIOLENCE
Cerulli C 1 , Lavigne J 2 , Richards H 1 , Caine E 1 1 University of Rochester, Rochester, NY, USA, 2 St. John Fisher College, Rochester, NY, USA OBJECTIVES: The productivity costs of intimate partner violence (IPV) have received considerable attention by human resource experts, employers and news outlets, including the BBC and Washington Post. Absences, tardiness and turnover have been estimated. Yet, validated estimates of "presenteeism" (functioning at work) are unknown. METHODS: In 2007, 190 female IPV victims petitioning a US court for orders for protection (OP) consented to participate in a randomized control trial which included the validated Work Limitations Questionnaire, the SF-12v2, the CES-D (for depression and anxiety), the CTS2S and the Danger Assessment. The WLQ is sensitive to changes in depression and anxiety over time and to a variety of medical and behavioral health conditions. We report descriptive statistics and univariate comparisons of working and non-working subjects using the WLQ. The paper will include multivariate analyses controlling for mental health and overall health status, neighborhood poverty rates and household characteristics, and comparisons among scales of specifi c domains (time management, mental/social performance, physical, output). The sample is comprised of 122 subjects who completed time two assessments. RESULTS: Employed subjects report a mean WLQ Productivity Loss Score of 94.3 (range 75.13-100; s.d. 6.28), representing a performance loss while working, of 5.7% (or 4.6 hours over 2 weeks of full-time employment) compared to the healthy worker norm. Employed women (n 75) reported better health, less danger, and less severe mental health symptoms than those outside of the workforce (n 47) at the time of their OP Petitions. CONCLUSIONS: To our knowledge, these are the fi rst estimates of work loss reported by IPV victims. When considered on a continuum of burden of illness due to work productivity loss, preliminary data suggest this population has a greater burden of illness than breast cancer survivors, but a lower burden than employees with active major clinical depression. 6%. The number of prescription refi lls of the near elderly increased 10.35%, while there was only 4.3% increase among the Medicare benefi ciaries. ER visits among the Medicare FFS group declined 2.6%, while the number of ER visits among the near elderly increased 0.94%. There was only small growth rate difference in other outcomes variable. CONCLUSIONS: Evidence from the MEPS data set suggests that Medicare Part D reduced out of pocket costs, drug utilization, and ER visits among patients without prior coverage. While cost reduction was expected, the reduction in utilization of drugs was not. Future research should further examine these trends.
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PIH45 THE IMPACT OF MEDICARE PART D ON HEALTH CARE UTILIZATION AND HEALTH OUTCOMES FOR MEDICARE BENEFICIARIES WITHOUT PREVIOUS DRUG COVERAGE
PIH46 OUTCOMES AND COSTS ASSOCIATED WITH FERTILITY DRUG THERAPY IN AN INSURED POPULATION WITH A STATE FERTILITY MANDATE
Bowen KL Excellus BlueCross BlueShield, Rochester, NY, USA OBJECTIVES: To estimate the proportion of all very-low and moderately-low-birthweight (VLBW, MLBW) infants and the short-term costs associated with fertility therapy in an insured population with a state mandate that requires coverage for fertility drugs but not in vitro fertilization (IVF) or drugs used with IVF. METHODS: The study sample consists of all live births, [2003] [2004] [2005] [2006] [2007] , that could be linked to mothers with continuous pharmacy and medical benefi ts eligibility during the 11 months before delivery, within a geographically defi ned subset of a commercially insured population. Likely causal relationships with fertility therapy are deduced and categorized as clomiphene or follicle-stimulating hormone (FSH) / intrauterine insemination (IUI) or IVF, based on the intervals between the dates of delivery and claims for IUI, clomiphene, FSH, or embryo transfer. Birthweight is categorized from claims coding. Maternal and infant claims charge distributions are characterized. RESULTS: Of 31,708 live births from 30,905 deliveries by 27,195 distinct women, clomiphene, FSH, and FSH IVF categories respectively account for 4.2%, 2.8%, 0.7% of the total number; 8.9%, 16.4%, 3.9% of all VLBW; 8.7%, 12.1%, 3.5% of all MLBW. Mean infant charges during the 12 months after birth were not signifi cantly different from other infants in the same birthweight categories. Mean charges during fi rst 12 months for all VLBW, MLBW, and other infants were, respectively, $248,600, $33,560, $6,990, and low-birthweight infants collectively accounted for 41.6% of all claims charges for infants. Differences in mean maternal charges are explained by fertility therapy, Caesarian section, and multiple gestation. CONCLUSIONS: Analysis of administrative claims data can supplement IVF registry data and published single or multicenter studies to inform models that predict outcomes and costs associated with different policy choices.
PIH47 POTENTIALLY INAPPROPRIATE MEDICATION USE IN ELDERLY USING JAPANESE BEERS CRITERIA
Akazawa M 1 , Imai H 2 , Igarashi A 3 1 University of Tokyo, Bunkyo-ku, Tokyo, Japan, 2 National Institute of Public Health, Wako, Saitama, Japan, 3 University of Tokyo, Bunkyo, Tokyo, Japan OBJECTIVES: Japanese version of Beers criteria (JP-BC) for potentially inappropriate medications in elderly patients was developed by consensus among nine specialists in order to refl ect regional medical practice and available medications. The prevalence of, and risk factors and medical costs associated with JP-BC were examined. METHODS: A cross-sectional study was conducted using health insurance claims data in Japan. Patients aged 65 years or older and had a pharmacy claim between October 2006 and September 2007 were selected and the use of JP-BC was identifi ed. Associations with patient demographics, health care utilization patterns and co-morbidities were assessed using logistic regression models. Medical costs associated with the JP-BC were also examined using generalized linear models. RESULTS: Among 6991 old patients, 41.2% were used one of the JP-BC. Commonly used medications were H2 blockers (19.5%), benzodiazepines (10.9%) and anticholinergics and antihistamines (7.8%). Patients with multiple medications, long-term inpatient care and multiple chronic conditions including gastrointestinal and cardiovascular diseases were more likely to use JP-BC. Mean annual cost for JP-BC users was 517,516 yen (5,625 US$), which was 2.4 times higher than that in non JP-BC users. Cost differences were still observed after risk adjustment using Charlson or Elixhauser co-morbidities. High medical costs among JP-BC users were partly explained by their high likelihood of multiple medications and long-term inpatient care. CONCLUSIONS: The prevalence of potentially inappropriate medication use in Japan was relatively higher than those previously reported in other countries even though regional specifi c medications were considered. Drug utilization reviews using the criteria must be promoted to increase awareness of inappropriate pharmaceutical cares among elderly and control medical costs.
PIH48 RELATIONSHIP BETWEEN DRUG COST COVERAGE AND PRESCRIPTION DECISION MAKING IN MEDICARE PART D ENROLLEES
Hales JW J 1 , Dudley S 2 , Hegamin A 1 , Poulios N 3 , Mills K 1 1 TUI University, Cypress, CA, USA, 2 Meharry Medical College, Nashville, TN, USA, 3 City University of New York, New York, NY, USA OBJECTIVES: The Medicare Part D prescription drug benefi t was introduced for Medicare enrollees to obtain prescription drug coverage. The 2006 benefi t did not provide insurance coverage for standard prescription drug plan (PDP) members who incurred prescription costs between $2250 and $3600 dollars (referred to as the "doughnut hole"). We evaluated whether the "doughnut hole" was a factor in altering the prescription fulfi llment decisions of Part D members. METHODS: In the current retrospective cohort study, 750 pharmacy adjudication records from a national Part D HMO pharmacy database were investigated for the year 2006. Five hundred participants (standard PDP members) without coverage in the doughnut hole were compared to a group of 250 participants (enhanced PDP members) whose prescription coverage did not lapse in the doughnut hole. All participants were analyzed via a multivariate strategy for their prescription fulfi llment decisions which were recorded as an endpoint of fi lling, delaying, switching, or stopping their respective medication. RESULTS: From 72% of the standard PDP members who experienced the doughnut hole and altered their prescription decision, it was determined that 22% delayed
